Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis
Authors: Theuriet Julian , Masingue Marion , Behin Anthony , Ferreiro Ana , Bassez Guillaume , Jaubert Pauline , Tarabay Oriana , Fer Frédéric , Pegat Antoine , Bouhour Françoise , Svahn Juliette , Petiot Philippe , Jomir Laurentiu , Chauplannaz Guy , Cornut-Chauvinc Catherine , Manel Véronique , Salort-Campana Emmanuelle , Attarian Shahram , Fortanier Etienne , Verschueren Annie , Kouton Ludivine , Camdessanché Jean-Philippe , Tard Céline , Magot Armelle , Péréon Yann , Noury Jean-Baptiste , Minot-Myhie Marie-Christine , Perie Maud , Taithe Frederic , Farhat Yacine , Millet Anne-Laure , Cintas Pascal , Solé Guilhem , Spinazzi Marco , Esselin Florence , Renard Dimitri , Sacconi Sabrina , Ezaru Andra , Malfatti Edoardo , Mallaret Martial , Magy Laurent , Diab Eva , Merle Philippe , Michaud Maud , Fournier Maxime , Pakleza Aleksandra Nadaj , Chanson Jean-Baptiste , Lefeuvre Claire , Laforet Pascal , Richard Pascale , Sternberg Damien , Villar-Quiles Rocio-Nur , Stojkovic Tanya , Eymard Bruno 
Published: May 2024

Congenital myasthenic syndromes (CMS) are clinically and genetically heterogeneous diseases caused by mutations affecting neuromuscular transmission. Even if the first symptoms mainly occur during childhood, adult neurologists must confront this challenging diagnosis and manage these patients throughout their adulthood. However, long-term follow-up data from large cohorts of CMS patients are lacking, and the long-term prognosis of these patients is largely unknown.

We report the clinical features, diagnostic difficulties, and long-term prognosis of a French nationwide cohort of 235 adult patients with genetically confirmed CMS followed in 23 specialized neuromuscular centres. Data were retrospectively analysed.

Of the 235 patients, 123 were female (52.3%). The diagnosis was made in adulthood in 139 patients, 110 of whom presented their first symptoms before the age of 18. Mean follow-up time between first symptoms and last visit was 34 years [standard deviation (SD) = 15.1]. Pathogenic variants were found in 19 disease-related genes. CHRNE-low expressor variants were the most common (23.8%), followed by variants in DOK7 (18.7%) and RAPSN (14%). Genotypes were clustered into four groups according to the initial presentation: ocular group (CHRNE-LE, CHRND, FCCMS), distal group (SCCMS), limb-girdle group (RAPSN, COLQ, DOK7, GMPPB, GFPT1), and a variable-phenotype group (MUSK, AGRN). The phenotypical features of CMS did not change throughout life. Only four genotypes had a proportion of patients requiring intensive care unit admission that exceeded 20%: RAPSN (54.8%), MUSK (50%), DOK7 (38.6%) and AGRN (25.0%). In RAPSN and MUSK patients most ICU admissions occurred before age 18 years and in DOK7 and AGRN patients at or after 18 years of age. Different patterns of disease course (stability, improvement and progressive worsening) may succeed one another in the same patient throughout life, particularly in AGRN, DOK7 and COLQ. At the last visit, 55% of SCCMS and 36.3% of DOK7 patients required ventilation; 36.3% of DOK7 patients, 25% of GMPPB patients and 20% of GFPT1 patients were wheelchair-bound; most of the patients who were both wheelchair-bound and ventilated were DOK7 patients. Six patients died in this cohort. The positive impact of therapy was striking, even in severely affected patients.

In conclusion, even if motor and/or respiratory deterioration could occur in patients with initially moderate disease, particularly in DOK7, SCCMS and GFPT1 patients, the long-term prognosis for most CMS patients was favourable, with neither ventilation nor wheelchair needed at last visit. CHRNE-LE patients did not worsen during adulthood and RAPSN patients, often severely affected in early childhood, subsequently improved.